Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2025-03-28 Board/Management Inform…
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details the appointment of a new outside director following a general meeting of shareholders. This falls under the category of Board/Management Information, specifically regarding changes in the board composition.
2025-03-28 Korean
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (이중항체 면역항암제 ABL103의 제1b/2상 임상시험계획 (IND) 승인 신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from ABL Bio regarding an amendment to a previously submitted clinical trial application (IND) for their drug ABL103. It details the addition of a regulatory body (MFDS) and updates the application date. Since this is a specific regulatory announcement regarding clinical trial status and does not fit into categories like financial reports, dividends, or shareholder meetings, it falls under the 'Regulatory Filings' category.
2025-03-21 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (이중항체 면역항암제 ABL103의 제1b/2상 임상시험계획 (IND) 승인 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the application for approval of a Phase 1b/2 clinical trial (IND) for the drug ABL103. This is a standard regulatory disclosure for biotech companies announcing clinical trial milestones. Since it does not fit into specific categories like financial reports, dividends, or board changes, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2025-03-19 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of an upcoming Annual General Meeting (AGM) for ABL Bio, detailing the date, location, and agenda items such as financial statement approval, director appointments, and remuneration limits. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their participation/votes. Therefore, it is classified as a Proxy Solicitation & Information Statement (PSI).
2025-03-13 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company, ABL Bio, is holding its AGM on a date that coincides with other companies' meetings. Since this is a specific regulatory disclosure regarding meeting logistics and compliance with the KOSDAQ Association's guidelines, and does not fit into the specific categories for AGM materials, proxy statements, or voting results, it is best classified as a general regulatory filing.
2025-03-13 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Independent Auditor's Report' (감사보고서) for ABL Bio, covering the fiscal year ending December 31, 2024. It includes the auditor's opinion, consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. This is a formal audit report, not an annual report (10-K) or a simple announcement, fitting the definition of an Audit Report (AR). FY 2024
2025-03-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.